BullBD Old Apps Site
Home
Details Chart Today news Share news Top gainer Top Looser Upcoming events
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 1 2 3 4 5 6 7 8 9 All
Bank Cement Ceramics Sector Corporate Bond Engineering Financial Institutions Food & Allied Fuel & Power IT Sector Insurance Jute Life Insurance Miscellaneous Mutual Funds Paper & Printing Pharmaceuticals & Chemicals Services & Real Estate Tannery Industries Telecommunication Textile Travel & Leisure All
  • Details
  • Chart
  • News

BXPHARMA

All Eps Dividend Board Agm Q1 Q2 Q3

BXPHARMA 02-Oct-2019

Credit Rating Information and Services Limited (CRISL) has rated the Company as "AA+" in the long term and "ST-1" in the short term along with a stable outlook in consideration of its audited financials up to June 30, 2018, unaudited financials up to March 31, 2019 and other relevant quantitative as well as qualitative information up to the date of rating declaration.

BXPHARMA 29-Apr-2019

(Q3 Un-audited): Consolidated EPS was Tk. 1.84 for January-March 2019 as against Tk. 1.49 for January-March 2018; Consolidated EPS was Tk. 5.51 for July 2018-March 2019 as against Tk. 4.74 for July 2017-March 2018. Consolidated NOCFPS was Tk. 6.48 for July 2018-March 2019 as against Tk. 3.83 for July 2017-March 2018. Consolidated NAV per share was Tk. 70.99 as on March 31, 2019 and Tk. 65.26 as on March 31, 2018.

BXPHARMA 21-Apr-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 28, 2019 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended on March 31, 2019.

BXPHARMA 30-Jan-2019

(Q2 Un-audited): Consolidated EPS was Tk. 1.81 for October-December, 2018 as against Tk. 1.66 for October-December, 2017; Consolidated EPS was Tk. 3.67 for July-December, 2018 as against Tk. 3.25 for July-December, 2017. Consolidated NOCFPS was Tk. 2.10 for July-December, 2018 as against Tk. 3.14 for July-December, 2017. Consolidated NAV per share was Tk. 69.15 as on December 31, 2018 and Tk. 63.77 as on December 31, 2017.

BXPHARMA 23-Jan-2019

As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2019 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended on December 31, 2018.

BXPHARMA 21-Jan-2019

The Company has informed that it has disbursed the cash dividend for the year ended on June 30, 2018 to the respective shareholders' Bank Accounts through BEFTN system.

BXPHARMA 26-Nov-2018

Trading of the shares of the Company will resume on 27.11.2018 after record date.

BXPHARMA 25-Nov-2018

Trading of the shares of the Company will remain suspended on record date i.e., 26.11.2018 for EGM and AGM.

BXPHARMA 20-Nov-2018

Trading of the shares of the Company will be allowed only in the Spot Market and Block transactions will also be settled as per Spot settlement cycle with cum benefit from 22.11.2018 to 25.11.2018. Trading of the shares of the Company will remain suspended on record date i.e., 26.11.2018 for EGM and AGM.

BXPHARMA 14-Nov-2018

(Q1 Un-audited): Consolidated EPS was Tk. 1.86 for July-September, 2018 as against Tk. 1.59 for July-September, 2017; Consolidated NOCFPS was Tk. 1.05 for July-September, 2018 as against Tk. 1.56 for July-September, 2017. Consolidated NAV per share was Tk. 68.59 as on September 30, 2018 and Tk. 63.36 as on September 30, 2017. As the company acquired Nuvista Pharma on 2.4.18, the comparative prior period figures are reported in the consolidated figures.

Previous Next page